339 related articles for article (PubMed ID: 22056141)
21. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
22. Brain lesions in tuberous sclerosis complex. Review.
Grajkowska W; Kotulska K; Jurkiewicz E; Matyja E
Folia Neuropathol; 2010; 48(3):139-49. PubMed ID: 20924998
[TBL] [Abstract][Full Text] [Related]
23. The role of TSC1 and TSC2 proteins in neuronal axons.
Karalis V; Wood D; Teaney NA; Sahin M
Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
[TBL] [Abstract][Full Text] [Related]
24. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
26. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
27. Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle.
Zhou J; Shrikhande G; Xu J; McKay RM; Burns DK; Johnson JE; Parada LF
Genes Dev; 2011 Aug; 25(15):1595-600. PubMed ID: 21828270
[TBL] [Abstract][Full Text] [Related]
28. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
29. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
30. Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma.
Sarnat HB; Flores-Sarnat L
Brain Dev; 2015 Jun; 37(6):553-62. PubMed ID: 25451314
[TBL] [Abstract][Full Text] [Related]
31. Postnatal neurogenesis generates heterotopias, olfactory micronodules and cortical infiltration following single-cell Tsc1 deletion.
Feliciano DM; Quon JL; Su T; Taylor MM; Bordey A
Hum Mol Genet; 2012 Feb; 21(4):799-810. PubMed ID: 22068588
[TBL] [Abstract][Full Text] [Related]
32. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases.
Kassai H; Sugaya Y; Noda S; Nakao K; Maeda T; Kano M; Aiba A
Cell Rep; 2014 Jun; 7(5):1626-1639. PubMed ID: 24857653
[TBL] [Abstract][Full Text] [Related]
33. A novel mouse model of tuberous sclerosis complex (TSC): eye-specific Tsc1-ablation disrupts visual-pathway development.
Jones I; Hägglund AC; Törnqvist G; Nord C; Ahlgren U; Carlsson L
Dis Model Mech; 2015 Dec; 8(12):1517-29. PubMed ID: 26449264
[TBL] [Abstract][Full Text] [Related]
34. The neurobiology of the tuberous sclerosis complex.
Marcotte L; Crino PB
Neuromolecular Med; 2006; 8(4):531-46. PubMed ID: 17028374
[TBL] [Abstract][Full Text] [Related]
35. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
36. Biallelic Mutations in
Winden KD; Sundberg M; Yang C; Wafa SMA; Dwyer S; Chen PF; Buttermore ED; Sahin M
J Neurosci; 2019 Nov; 39(47):9294-9305. PubMed ID: 31591157
[TBL] [Abstract][Full Text] [Related]
37. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
Ma L; Teruya-Feldstein J; Bonner P; Bernardi R; Franz DN; Witte D; Cordon-Cardo C; Pandolfi PP
Cancer Res; 2007 Aug; 67(15):7106-12. PubMed ID: 17671177
[TBL] [Abstract][Full Text] [Related]
38. mTOR-related neuropathology in mutant tsc2 zebrafish: Phenotypic, transcriptomic and pharmacological analysis.
Scheldeman C; Mills JD; Siekierska A; Serra I; Copmans D; Iyer AM; Whalley BJ; Maes J; Jansen AC; Lagae L; Aronica E; de Witte PAM
Neurobiol Dis; 2017 Dec; 108():225-237. PubMed ID: 28888969
[TBL] [Abstract][Full Text] [Related]
39. Loss of Tsc1 accelerates malignant gliomagenesis when combined with oncogenic signals.
Yamada D; Hoshii T; Tanaka S; Hegazy AM; Kobayashi M; Tadokoro Y; Ohta K; Ueno M; Ali MA; Hirao A
J Biochem; 2014 Apr; 155(4):227-33. PubMed ID: 24368778
[TBL] [Abstract][Full Text] [Related]
40. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.
Malik AR; Liszewska E; Skalecka A; Urbanska M; Iyer AM; Swiech LJ; Perycz M; Parobczak K; Pietruszka P; Zarebska MM; Macias M; Kotulska K; Borkowska J; Grajkowska W; Tyburczy ME; Jozwiak S; Kwiatkowski DJ; Aronica E; Jaworski J
Acta Neuropathol Commun; 2015 Jul; 3():48. PubMed ID: 26220190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]